@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech
@JohnCFierce: I used to make fun of $PFE's big in-licensing deals (remember Medivation and Alzheimer's?) I'm switching to out-licensing now (neratinib). | Follow @JohnCFierce
@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. More | Follow @DamianFierce
@EmilyMFierce: Ebola treatments caught in limbo. Nature piece | Follow @EmilyMFierce
> The FDA has raised concerns about Impax Lab's ($IPXL) manufacturing facility in Taiwan, sparking fears that it may further delay the biotech's Parkinson's drug Rytary, which was earlier held up by manufacturing woes in California. Story
> Shares of Galectin Therapeutics ($GALT) got hammered yesterday following a cohort analysis which it insists is positive. Today the biotech blamed "social media" for the meltdown, which included some harsh criticism. Release
Medical Device News
@FierceMedDev: Dental implant player Nobel Biocare is the latest med tech M&A target. Story | Follow @FierceMedDev
@StacyALawrence: Large healthcare customers squeeze med tech supplier Owens & Minor. Article | Follow @StacyALawrence
@VarunSaxena2: AcelRx discusses sublingual painkiller's rejection with concerned investors. FierceDrugDelivery article | Follow @VarunSaxena2
@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce
@EmilyWFierce: Epic Sciences ropes in $PFE and $RHHBY funding to commercialize CTC tests for cancer treatment. FierceDiagnostics story | Follow @EmilyWFierce
> Kickstarter in vogue as funding mechanism for new devices. Story
> What will changes to the Sunshine Act mean for devicemakers? Item
> Coloplast adding 150 jobs in the U.K. to boost chronic care business. Article
Pharma News
@FiercePharma: Popular on FiercePharmaMarketing: Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story | Follow @FiercePharma
@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton
@EricPFierce: Hikma builds more heft in sterile manufacturing. Say it will take equipment out of closed Ben Venue plant. News | Follow @EricPFierce
@CarlyHFierce: Today in FiercePharmaMarketing: Doom for combo meds? PBMs dump 2-in-1 drugs; 'Name-calling' at FDA. Issue | Follow @CarlyHFierce
> Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts. Story
> A $635M win-win deal boosts Pfizer in vaccines, slims Baxter for spinoff. Article
> Amgen makes deep job cuts to position itself for post Enbrel-world. More
> Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebid. News
Drug Delivery News
> Amid fears of shortage of antibiotics, DNA origami technique developed to combat E. coli, other bugs. Article
> Nanoparticles deliver agents to spur immune system into action against cancer. Story
> Developer of unique delivery technology for eye care expanding in Europe. Item
> Nature-inspired artificial cilia could help move drugs to a target. More
> AcelRx discusses sublingual painkiller's rejection with concerned investors. Article
Diagnostics News
> In Q2, diagnostics venture investment showed some signs of life. More
> Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table. Article
> Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test. Story
> Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. Article
> Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device. Item
Pharma Marketing News
> Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs. Report
> Name-calling: The FDA needs your ideas for locking down brand monikers. More
> AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits. More
> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story
> Merck spokeswoman: Sales layoffs to hit PA-based field reps. Article